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Abstract
The identification of a good prognostic factor of neurological outcome after cardiac arrest is
needed. S-100B protein seems to be a promising early predictor of brain damage. Yet it is
necessary to reach a consensus on cut-off values, time of blood sampling and the predictive
accuracy of S-100B protein. The present review summarizes the data about the clinical impli-
cations of S-100B protein after brain injury, especially in patients after cardiac arrest. (Cardiol J
2010; 17, 5: 532–536)
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As the techniques of cardiopulmonary resusci-
tation (CPR) become more effective, the number of
patients surviving cardiac arrest (CA) increases. High
mortality and frequent brain damage are characte-
ristic of these  patients but there are no precise and
generally accepted diagnostic rules to predict ear-
ly and overall outcomes. The identification of a good
prognostic factor of the neurological outcome after
CA is needed to decide on further therapeutic man-
agement and to avoid futile medical treatment.
To predict cerebral outcomes following CA,
modern medicine has at its disposal neuroimaging
data, electrophysiological data and blood or cere-
brospinal fluid examination data. Neuroimaging and
electrophysiological data, however, are insufficient
in the early stage to appraise brain injury following
CA and are not as helpful as early biochemical mark-
ers, which are easy to obtain and assess [1]. Many
investigators have been looking for the most accu-
rate predictor [2–5]. S-100B protein and neuron-spe-
cific enolase (NSE) appear to be the most promising
factors. The present review focuses on the role of
S-100B protein as an earlier marker than NSE in
predicting early neurological outcomes following CA.
S-100B is a calcium-binding, low molecular
weight (LMW) protein produced by activated glia
in the central nervous system. Its name S-100B
originates from its solubility in a 100%-saturated
solution with ammonium sulphate at neutral pH [6].
S-100B is produced early after metabolic injury by
astrocytes activated by oxygen or glucose depriva-
tion [7]. It is released into the extracellular space,
into cerebrospinal fluid and further into the blood-
stream when the blood-brain barrier loses its inte-
grity, mechanically or during inflammatory response
after CA. It may also be released from mechanical-
ly damaged cells. In nanomolar concentrations,
S-100B is trophic to neurons and has a reparative
role but when it is overproduced, in micromolar con-
centrations can enhance neuroinflammation and
cause further neurologic injury by evoking neuronal
apoptosis [8]. Serum levels of S-100B increase af-
ter CA and are positively correlated with dimension
of brain injury [7, 8]. S-100B is measured in blood
serum and remains stable for several hours. It has
a short half-life (approximately 30 min) so its mea-
surement is very useful in the emergency and in-
tensive care units.
Many different sensitive immunoassays are
available to determine the serum levels of S-100B
protein, both automatic and manual [9, 10]. One of
the most popular tests, Can Ag S100 EIA (Can Ag
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Diagnostics AB, Gothenburg, Sweden) contains
reagents for 96 tests and has to be stored at 2–8°C.
The estimations of S-100B are done at room tem-
perature, and among other things require micro-
plate spectrophotometer and microplate shaker.
Calibrators and patient samples are incubated to-
gether with Anti-S-100B monoclonal antibody in
Streptavidin-coated microstrips for two hours. Af-
ter incubation they are washed and incubated with
two more reagents. If S-100B is present, a blue color
will develop during the enzyme reaction. The in-
tensity of this color is proportional to the amount
of S-100B in the samples. The absorbance is read
at 620 nm in a microplate spectrophotometer.
Another of the many tests available is the po-
pular two-site immunoassay Liaison® Sangtec 100
(DiaSorin AB, Bromma, Sweden). It’s a two-step
immunoluminometric sandwich assay using directly
coated magnetic microparticles and it allows 100 de-
terminations of S-100B to be carried out. The time
of incubation is 20 minutes.
Many studies on the S-100B protein as an early
predictor following CA have been published (Table 1).
Pfeifer et al. [11] investigated the prognostic value
of S-100B protein, NSE, and Glasgow Coma Scale
(GCS) in 97 patients following CA. Serum levels
over 1.5 µg/L for S-100B increased the risk of a poor
outcome (death/persistent vegetative state) by 12.6
times. A combination of GCS < six and elevated
serum levels of S-100B and NSE at 72 hours after
CPR predicted poor outcome with 100% specificity.
A Japanese study by Shinozaki et al. [12] com-
pared serum levels of S-100B and NSE at six and
24 hours following CA in 107 patients. Serum lev-
els of S-100B and NSE in the group of patients with
a poor neurological outcome (CPC3 to CPC5 in the
Glasgow-Pittsburgh cerebral performance catego-
ries: CPC, Table 2) were higher than those in pa-
tients with a favorable neurological outcome (CPC1
and CPC2; p < 0.01). Cut-off values of S-100B pre-
dictive of poor neurological outcome were 1.41,
0.21, and 0.05 ng/mL. They corresponded to sensi-
tivities of 20.9%, 62.8%, and 100%. These values
were higher than these for NSE. S-100B assessed
24 hours after CA is recognized as a better early
predictor of poor neurological outcome than NSE.
Table 1. Studies on S-100B levels, with cut-off values, specificity, sensitivity and time of sampling in
patients following cardiac arrest.
Authors No. of Data Outcome Cut-off Specificity (%)/ Time of
patients values [µg/L]  Sensitivity (%) sampling
Martens et al. [16] 64 S-100, NSE Remained in coma 0.7 96/55 24 h
Rosén et al. [25] 41 S-100 Death 0.2 Day 1
0.2 Day 2
No return to 0.2 Day 2
independent
daily life
Böttiger et al. [13] 66 S-100B Death 0.2 24 h
Brain damage > 1.1 NM/100 48 h
Hachimi-Idrissi 58 S-100B Remained 0.7 85/67 OA
et al. [15] in coma 0.7 88/100  24 h
Mussack et al. [18] 20 S-100B, Il-8 No return to 0.76 100/54 Day 1
independent
daily life
Pfeifer et al. [11] 97 S-100B, NSE, Remained in 1.5 96/34 Day 3
time of anoxia, coma
GCS score
Miao et al. [14] 25 S-100B, NSE Remained in coma 0.165 100/94.4 2 h
Grubb et al. [17] 143 S-100B, NSE In-hospital death 1.20 100/44.8 Day 2
Memory impairment > 0.29 100/42.8
Prohl et al. [2] 80 S-100B, NSE, Remained in coma 2.1 100/17 Day 1
sensory-evoked
potentials,
neuropsychological
assessments
Shinozaki et al. [12] 107 S-100B, NSE CPC 3–5 1.41 100/20.9 24 h
NSE — neuron specific enolase; Il-8 — interleukin-8; GCS — Glasgow Coma Scale; CPC — cerebral performance categories; NM — not mentioned;
OA — on admission
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Also Böttiger et al. [13] determined serum le-
vels of S-100B and NSE in 66 patients after CA, im-
mediately afterwards, and after 15, 30, 45 and
60 minutes; again after two, eight, 24, 48, and 72 hours;
and seven days after CPR (NSE was not determined
before two hours after CA). During the entire study
period, S-100 and NSE levels were lower in patients
surviving without brain damage (CPC1) than in the
group with documented brain damage. Within two
hours after CA, the maximum S-100 level in
patients with documented brain damage was 3.70 ±
± 0.77 µg/L (p < 0.05), and in patients without re-
covery of spontaneous circulation (ROSC) 3.44 ±
± 0.58 µg/L (p < 0.05), whereas in patients with no
brain damage S-100 level was 0.90 ± 0.29 µg/L. In-
vestigators concluded that S-100B is an early and
sensitive marker of severe brain damage and short-
-term outcome following CA.
Moreover, Miao et al. [14] in a study from Chi-
na compared serum levels of S-100B and NSE at
two, 12, 24, 48 and 72 hours after ROSC, in a group
of seven healthy volunteers and in 25 patients di-
vided into two groups: patients who regained con-
sciousness during the six months following CA, and
patients who did not. Serum levels of both NSE and
S-100 were higher in the group who did not regain
consciousness. Serum S-100 protein cut-off was
0.165 µg/L, with a sensitivity of 94.4%, and a speci-
ficity of 100%.
Serum levels of S-100B were assessed at ad-
mission in a group of 58 patients who had CA by
Hachimi-Idrissi et al. [15]. In patients who did not
regain consciousness, serum levels of S-100B were
higher 4.66 ± 0.61 µg/L than in the patients who re-
gained consciousness 0.84 ± 0.21 µg/L (p < 0.01).
Serum S-100 cut-off value of > 0.7 µg/L 24 hours
after CA was found to be a predictor of poor prog-
nosis (specificity of 88% and sensitivity of 100%),
was recently reported by Martens et al. [16] with
higher specificity of 96%.
Furthermore, Grubb et al. [17] obtained S-100
and NSE levels in 143 survivors following CA, at
12, 24–48 and 72–96 hours after the event. Cut-off
values of S-100 resulting 100% specificity for in-
hospital death were 1.20 µg/L (sensitivity 44.8%);
and for moderate to severe memory impairment
> 0.29 µg/L (sensitivity 42.8%).
In turn, Mussack et al. [18] compared S-100 and
Il-8 levels in 20 patients after CA and 20 patients
after brain injury. In CA-patients, the S-100 level
measured 12 hours after CA was an independent
predictor for unfavorable neurological outcome (in
Glasgow Outcome Scale score Table 2).
A very interesting systematic review of 31 pa-
pers discussing S-100B and NSE was presented by
Shinozaki et al. [1]. Investigators compared cut-off
levels, definitions of poor and good outcomes, and
time of sampling. Their study showed that the mea-
surement of serum levels of S-100B within the
24 hours following CA might be more relevant than
those of NSE in predicting neurological outcomes.
S-100B is also useful in determining the outcome
after trauma and stroke. Researchers concluded
that serum levels of S-100B indicate the severity
of brain damage and are correlated to neurological
prognosis after trauma [19, 20]. They also showed
Table 2. Comparison of Glasgow-Pittsburgh cerebral performance categories (CPC) and Glasgow
Outcome Scale (GOS) scores.
CPC grade CPC specification GOS specification GOS grade
1 Good cerebral performance: Good recovery: able to 5
conscious and alert, with  return to work or school
normal neurological function
or only slight cerebral disability
2 Moderate cerebral disability: Moderate disability: able to 4
conscious and sufficient cerebral live independently but
function for part-time work in unable to return to work or school
sheltered environment or
independent activities of daily life
3 Severe cerebral disability: Severe disability: able to 3
conscious and dependent follow commands but
on others for daily support unable to live independently
because of impaired brain function
4 Coma, vegetative state 2
5 Dead or brain dead 1
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that integration of S-100B within existing manage-
ment routines can reduce the need for computed
tomography scans after minor head injury by 30%
[21]. When it comes to the outcome prediction af-
ter stroke, most investigators agree that S-100B is
a useful marker [22, 23]. They also suggest that
S-100B may have a promising role as an additional
tool for identifying patients at increased risk of spe-
cific early neurological complications after stroke
in non-specialist hospitals [24].
The presented investigations have some limi-
tations. The main one is the small number of stu-
died patients. The second is the time course, but
no study has presented the time-course of S-100B
in a large number of human subjects at the same
time. Future studies should focus on it in a larger
group of patients.
Clinically, S-100B could be used to determine
patients with a low risk of brain damage which does
not require further diagnostic management. On the
other hand, in patients with a high risk of brain da-
mage, it could prevent the use of pointless therapy.
It could be assessed at admission, then between six
and 12 hours, and finally 24 hours after CA.
Most investigators agree that S-100B is an ear-
ly and specific predictor of poor neurological out-
come, and that it does this more accurately than
NSE [1, 11–13, 15–18, 25–29]. But for the moment,
a wide variety of cut-off values and different defini-
tions of poor and good outcomes present a barrier to
applying S-100 protein to clinical practice. It’s ne-
cessary to set cut-off values, time of blood sampling,
and to establish a coherent definition of poor and good
outcomes. From then on, serum levels of S-100B can
give us useful information about neurological out-
comes in cardiological patients following CA.
Conclusions
S-100B protein seems to be a good early prog-
nostic factor of brain damage after CA and other con-
ditions bringing about brain injury, such as stroke
and trauma.
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